Development of mRNA vaccines in response to the Public Health Emergency of International Concern

YE Qing; QIN Chengfeng

doi:10.12211/2096-8280.2023-072

您当前的位置：

首页 >

文章列表页 >

Development of mRNA vaccines in response to the Public Health Emergency of International Concern

Invited Review | 更新时间：2025-03-20

- Development of mRNA vaccines in response to the Public Health Emergency of International Concern
- Synthetic Biology Journal Vol. 5, Issue 2, Pages: 310-320(2024)
- 作者机构：
  
  军事科学院军事医学研究院微生物流行病研究所，病原微生物生物安全全国重点实验室，北京 100071
- 作者简介：
- 基金信息：
- DOI：10.12211/2096-8280.2023-072
  CLC： R183
- Received：07 October 2023，
  
  Revised：2024-01-29，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
叶青，秦成峰. “国际公共卫生紧急事件”下的mRNA疫苗研发［J］. 合成生物学， 2024， 5（2）： 310-320

YE Qing， QIN Chengfeng. Development of mRNA vaccines in response to the Public Health Emergency of International Concern［J］. Synthetic Biology Journal， 2024， 5（2）： 310-320
叶青，秦成峰. “国际公共卫生紧急事件”下的mRNA疫苗研发［J］. 合成生物学， 2024， 5（2）： 310-320 DOI： 10.12211/2096-8280.2023-072.

YE Qing， QIN Chengfeng. Development of mRNA vaccines in response to the Public Health Emergency of International Concern［J］. Synthetic Biology Journal， 2024， 5（2）： 310-320 DOI： 10.12211/2096-8280.2023-072.

摘要

“国际公共卫生紧急事件”（简称PHEIC）是指疾病的国际传播对其他国家构成公共卫生风险，需要采取协调一致的国际应对措施的不同寻常事件。迄今为止，世界卫生组织（WHO）一共宣布了7次PHEIC，包括甲型H1N1流感、埃博拉、脊髓灰质炎、寨卡、新型冠状病毒感染和猴痘疫情。疫苗是应对传染病疫情的有力武器，合成生物学的发展突破了传统疫苗存在的难点问题和技术瓶颈，为病毒性传染病防控提供了全新的思路，尤其是mRNA疫苗作为下一代疫苗研发的平台技术，具有安全性强、有效性良好、研发周期短、易规模化生产、易扩大产能等特点，在应对新突发传染病疫情方面具有明显的优势。目前，新冠mRNA疫苗已正式获批上市，针对流感、寨卡和猴痘病毒的多款mRNA疫苗已进入临床研究阶段，埃博拉mRNA疫苗处于临床前研究阶段，而针对脊髓灰质炎病毒尚无mRNA疫苗研究的报道。本文就历次PHEIC应对中mRNA疫苗的研发进展进行了详细梳理和评述，同时对mRNA疫苗应对PHEIC的未来发展趋势和挑战进行了展望和讨论。结合合成生物学、生物化学和人工智能等多学科技术对mRNA分子设计、高效递送以及疫苗生产和储存运输等进行优化，有望进一步提高mRNA疫苗的有效性和可及性。综上，尽管尚无法预知下一次PHEIC何时会出现，但当下一次PHEIC出现时，mRNA疫苗技术一定会成为人类防范PHEIC的有力武器。

Abstract

A Public Health Emergency of International Concern (PHEIC) is defined by the World Health Organization (WHO) as “an extraordinary event which is determined to constitute a public health risk to other states through the international spread of disease and potentially requires a coordinated international response”. To date

WHO has declared seven PHEIC events

including the H1N1 influenza

Ebola

poliomyelitis

Zika

COVID-19 and mpox. Vaccination remains as an effective method in preventing infectious diseases. The International Health Regulations (IHR) Emergency Committee's recommendations for preventing or reducing the international spread of disease and avoiding unnecessary interference with international traffic include an emphases on the development of diagnostics and therapeutics for diseases

as well as the vaccine development. The mRNA vaccine represents a platform technology for the development of next-generation vaccines

and possesses distinct advantages

such as a shortened development cycle

scalable and cost-effective production

as well as enhanced amplification capacity

highlighting its potential in rapid responding to emerging and re-emerging infectious diseases. In recent decades

the development of mRNA synthesis technology and nucleic acid delivery system has facilitated the rapid development of mRNA vaccines and their clinical applications. Here

we overview the development of mRNA vaccines in response to the past PHEICs

and discuss challenges and trends in this regard. Currently

COVID-19 mRNA vaccines have been authorized for human use

while multiple mRNA vaccines against influenza

Zika

mpox and Ebola have been evaluated in clinical or pre-clinical studies. Despite their proven efficacy

there is still room for further improvement of the mRNA vaccines. The mRNA design

optimization

delivery

formulation

manufacturing

storage

and transportation can be further improved by integrating synthetic biology

biochemistry

artificial intelligence

and other multidisciplinary technologies. Although the emergence of the next PHEIC cannot be predicted with certainty

we are optimistic that the mRNA vaccine technology will play a pivotal role in preventing pandemics in the future.

关键词

Keywords

references

KHAN K , ARINO J , HU W , et al . Spread of a novel influenza A (H1N1) virus via global airline transportation [J ] . The New England Journal of Medicine , 2009 , 361 ( 2 ): 212 - 214 .

GOSTIN L O , FRIEDMAN E A . Ebola: a crisis in global health leadership [J ] . The Lancet , 2014 , 384 ( 9951 ): 1323 - 1325 .

SOGHAIER M A , SAEED K M I , ZAMAN K K . Public health emergency of international concern (PHEIC) has declared twice in 2014; Polio and Ebola at the top [J ] . AIMS Public Health , 2015 , 2 ( 2 ): 218 - 222 .

PETERSEN L R , JAMIESON D J , POWERS A M , et al . Zika virus [J ] . The New England Journal of Medicine , 2016 , 374 ( 16 ): 1552 - 1563 .

Eurosurveillance Editorial Team . Ebola public health emergency of international concern, democratic republic of the Congo, 2019 [J ] . Eurosurveillance , 2019 , 24 ( 29 ): 190718e .

WHO . WHO Coronavirus (COVID-19) dashboard [EB/OL ] . [ 2023-10-01 ] . https://covid19.who.int/ https://covid19.who.int/ .

MITJÀ O , OGOINA D , TITANJI B K , et al . Monkeypox [J ] . The Lancet , 2023 , 401 ( 10370 ): 60 - 74 .

WILDER-SMITH A , OSMAN S . Public health emergencies of international concern: a historic overview [J ] . Journal of Travel Medicine , 2020 , 27 ( 8 ): taaa227 .

MASCOLA J R , FAUCI A S . Novel vaccine technologies for the 21st century [J ] . Nature Reviews Immunology , 2020 , 20 ( 2 ): 87 - 88 .

CHAUDHARY N , WEISSMAN D , WHITEHEAD K A . mRNA vaccines for infectious diseases: principles, delivery and clinical translation [J ] . Nature Reviews Drug Discovery , 2021 , 20 ( 11 ): 817 - 838 .

PARDI N , HOGAN M J , WEISSMAN D . Recent advances in mRNA vaccine technology [J ] . Current Opinion in Immunology , 2020 , 65 : 14 - 20 .

WOLFF J A , MALONE R W , WILLIAMS P , et al . Direct gene transfer into mouse muscle in vivo [J ] . Science , 1990 , 247 ( 4949 Pt 1 ): 1465 - 1468 .

KARIKÓ K , BUCKSTEIN M , NI H P , et al . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA [J ] . Immunity , 2005 , 23 ( 2 ): 165 - 175 .

SIMONSEN L , SPREEUWENBERG P , LUSTIG R , et al . Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study [J ] . PLoS Medicine , 2013 , 10 ( 11 ): e1001558 .

DAWOOD F S , IULIANO A D , REED C , et al . Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study [J ] . The Lancet Infectious Diseases , 2012 , 12 ( 9 ): 687 - 695 .

PAPPAS C , AGUILAR P V , BASLER C F , et al . Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2008 , 105 ( 8 ): 3064 - 3069 .

WATANABE T , TISONCIK-GO J , TCHITCHEK N , et al . 1918 Influenza virus hemagglutinin (HA) and the viral RNA polymerase complex enhance viral pathogenicity, but only HA induces aberrant host responses in mice [J ] . Journal of Virology , 2013 , 87 ( 9 ): 5239 - 5254 .

NACHBAGAUER R , KRAMMER F . Universal influenza virus vaccines and therapeutic antibodies [J ] . Clinical Microbiology and Infection , 2017 , 23 ( 4 ): 222 - 228 .

FREYN A W , RAMOS DA SILVA J , ROSADO V C , et al . A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice [J ] . Molecular Therapy , 2020 , 28 ( 7 ): 1569 - 1584 .

BAHL K , SENN J J , YUZHAKOV O , et al . Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses [J ] . Molecular Therapy , 2017 , 25 ( 6 ): 1316 - 1327 .

FELDMAN R A , FUHR R , SMOLENOV I , et al . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J ] . Vaccine , 2019 , 37 ( 25 ): 3326 - 3334 .

Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update [E B/OL ] . ( 2021-12-10 )[ 2023-10-01 ] . https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Positive-Interim-Phase-1-Data-for-mRNA-Flu-Vaccine-and-Provides-Program-Update/default.aspx https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Positive-Interim-Phase-1-Data-for-mRNA-Flu-Vaccine-and-Provides-Program-Update/default.aspx .

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate(mRNA-1010)[Eb/OL] . 2022-06-07[2023-10-01] . https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-3-Study-of-Seasonal-Influenza-Vaccine-Candidate-mRNA-1010/default.aspx https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-3-Study-of-Seasonal-Influenza-Vaccine-Candidate-mRNA-1010/default.aspx .

Moderna Announces First Participants Dosed in Phase 1 / 2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates [EB/OL ] . ( 2022-04-11 )[ 2023-10-01 ] . https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-12-Study-with-mRNA-1020-and-mRNA-1030-Seasonal-Influenza-Vaccine-Candidates/default.aspx https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-12-Study-with-mRNA-1020-and-mRNA-1030-Seasonal-Influenza-Vaccine-Candidates/default.aspx .

AREVALO C P , BOLTON M J , LE SAGE V , et al . A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes [J ] . Science , 2022 , 378 ( 6622 ): 899 - 904 .

JACOB S T , CROZIER I , FISCHER W A , et al . Ebola virus disease [J ] . Nature Reviews Disease Primers , 2020 , 6 ( 1 ): 13 .

WHO . Ebola outbreak 2014 - 2016 -West Africa[EB/OL ] . [ 2023-10-01 ] . https://www.who.int/emergencies/situations/ebola-outbreak-2014-2016-West-Africa https://www.who.int/emergencies/situations/ebola-outbreak-2014-2016-West-Africa .

CDC . 2014 - 2016 Ebola Outbreak in West Africa [EB/OL ] . [ 2023-10-01 ] . https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html .

WHO . Ebola virus disease Democratic Republic of Congo: external situation report 98 / 2020 [EB/OL ] . ( 2020-06-24 )[ 2023-10-01 ] . https://www.who.int/publications/i/item/10665-332654 https://www.who.int/publications/i/item/10665-332654 .

GHOSH S , SAHA A , SAMANTA S , et al . Genome structure and genetic diversity in the Ebola virus [J ] . Current Opinion in Pharmacology , 2021 , 60 : 83 - 90 .

HENAO-RESTREPO A M , CAMACHO A , LONGINI I M , et al . Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) [J ] . Lancet , 2017 , 389 ( 10068 ): 505 - 518 .

MILLIGAN I D , GIBANI M M , SEWELL R , et al . Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial [J ] . JAMA , 2016 , 315 ( 15 ): 1610 - 1623 .

ZHU F C , WURIE A H , HOU L H , et al . Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial [J ] . Lancet , 2017 , 389 ( 10069 ): 621 - 628 .

MALIK S , KISHORE S , NAG S , et al . Ebola virus disease vaccines: development, current perspectives & challenges [J ] . Vaccines , 2023 , 11 ( 2 ): 268 .

CHAHAL J S , KHAN O F , COOPER C L , et al . Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2016 , 113 ( 29 ): E4133 - E4142 .

MEYER M , HUANG E , YUZHAKOV O , et al . Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease [J ] . The Journal of Infectious Diseases , 2018 , 217 ( 3 ): 451 - 455 .

KRÄHLING V , ERBAR S , KUPKE A , et al . Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection [J ] . Molecular Therapy , 2023 , 31 ( 2 ): 374 - 386 .

PLATT L R , ESTÍVARIZ C F , SUTTER R W . Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden [J ] . The Journal of Infectious Diseases , 2014 , 210 ( Suppl 1 ): S380 - S389 .

WHO . Poliomyelitis [EB/OL ] . [ 2023-10-25 ] . https://www.who.int/news-room/fact-sheets/detail/poliomyelitis https://www.who.int/news-room/fact-sheets/detail/poliomyelitis .

MBANI C J , NEKOUA M P , MOUKASSA D , et al . The fight against poliovirus is not over [J ] . Microorganisms , 2023 , 11 ( 5 ): 1323 .

CUGOLA F R , FERNANDES I R , RUSSO F B , et al . The Brazilian Zika virus strain causes birth defects in experimental models [J ] . Nature , 2016 , 534 ( 7606 ): 267 - 271 .

IKEJEZIE J , SHAPIRO C N , KIM J , et al . Zika virus transmission-region of the americas, May 15, 2015—December 15, 2016 [J ] . MMWR Morbidity and Mortality Weekly Report , 2017 , 66 ( 12 ): 329 - 334 .

LINDENBACH B D , RICE C M . Molecular biology of flaviviruses [J ] . Advances in Virus Research , 2003 , 59 : 23 - 61 .

DAI L P , SONG J , LU X S , et al . Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody [J ] . Cell Host & Microbe , 2016 , 19 ( 5 ): 696 - 704 .

KIM S Y , ZHAO J , LIU X Y , et al . Interaction of Zika virus envelope protein with glycosaminoglycans [J ] . Biochemistry , 2017 , 56 ( 8 ): 1151 - 1162 .

HASAN S S , MILLER A , SAPPARAPU G , et al . A human antibody against Zika virus crosslinks the E protein to prevent infection [J ] . Nature Communications , 2017 , 8 : 14722 .

LIN H H , YIP B S , HUANG L M , et al . Zika virus structural biology and progress in vaccine development [J ] . Biotechnology Advances , 2018 , 36 ( 1 ): 47 - 53 .

RICHNER J M , HIMANSU S , DOWD K A , et al . Modified mRNA vaccines protect against Zika virus infection [J ] . Cell , 2017 , 169 ( 1 ): 176 .

PARDI N , HOGAN M J , PELC R S , et al . Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination [J ] . Nature , 2017 , 543 ( 7644 ): 248 - 251 .

BOLLMAN B , NUNNA N , BAHL K , et al . An optimized messenger RNA vaccine candidate protects non-human Primates from Zika virus infection [J ] . NPJ Vaccines , 2023 , 8 ( 1 ): 58 .

HUANG C L , WANG Y M , LI X W , et al . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J ] . The Lancet , 2020 , 395 ( 10223 ): 497 - 506 .

PULLIAM J R C , VAN SCHALKWYK C , GOVENDER N , et al . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa [J ] . Science , 2022 , 376 ( 6593 ): eabn4947 .

LIPSITCH M , KRAMMER F , REGEV-YOCHAY G , et al . SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact [J ] . Nature Reviews Immunology , 2022 , 22 ( 1 ): 57 - 65 .

HU B , GUO H , ZHOU P , et al . Characteristics of SARS-CoV-2 and COVID-19 [J ] . Nature Reviews Microbiology , 2021 , 19 ( 3 ): 141 - 154 .

SHANG J , YE G , SHI K , et al . Structural basis of receptor recognition by SARS-CoV-2 [J ] . Nature , 2020 , 581 ( 7807 ): 221 - 224 .

OU X Y , LIU Y , LEI X B , et al . Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV [J ] . Nature Communications , 2020 , 11 ( 1 ): 1620 .

HOFFMANN M , KLEINE-WEBER H , SCHROEDER S , et al . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [J ] . Cell , 2020 , 181 ( 2 ): 271 - 280.e8 .

LETKO M , MARZI A , MUNSTER V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses [J ] . Nature Microbiology , 2020 , 5 ( 4 ): 562 - 569 .

WALLS A C , PARK Y J , TORTORICI M A , et al . Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein [J ] . Cell , 2020 , 181 ( 2 ): 281 - 292.e6 .

WANG K , JIA Z J , BAO L , et al . Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants [J ] . Nature , 2022 , 603 ( 7903 ): 919 - 925 .

PICCOLI L , PARK Y J , TORTORICI M A , et al . Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology [J ] . Cell , 2020 , 183 ( 4 ): 1024 - 1042.e21 .

GREANEY A J , LOES A N , GENTLES L E , et al . The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD [EB/OL ] . bioRxiv 2021 : 2021 . 04 . 14 . 439844 ( 2021-04-14 )[ 2023-10-01 ] . https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1 https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1 .

JU B , ZHANG Q , GE J W , et al . Human neutralizing antibodies elicited by SARS-CoV-2 infection [J ] . Nature , 2020 , 584 ( 7819 ): 115 - 119 .

PINTO D , PARK Y J , BELTRAMELLO M , et al . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody [J ] . Nature , 2020 , 583 ( 7815 ): 290 - 295 .

RAPPAZZO C G , TSE L V , KAKU C I , et al . Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody [J ] . Science , 2021 , 371 ( 6531 ): 823 - 829 .

ZHOU Y J , LIU Z Z , LI S B , et al . Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD [J ] . Cell Reports , 2021 , 34 ( 5 ): 108699 .

WHO . COVID-19 vaccines with WHO emergency use listing [EB/OL ] . [ 2023-10-01 ] . https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing .

JACKSON L A , ANDERSON E J , ROUPHAEL N G , et al . An mRNA vaccine against SARS-CoV-2 - preliminary report [J ] . The New England Journal of Medicine , 2020 , 383 ( 20 ): 1920 - 1931 .

BADEN L R , EL SAHLY H M , ESSINK B , et al . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J ] . The New England Journal of Medicine , 2021 , 384 ( 5 ): 403 - 416 .

FRENCK R W JR , KLEIN N P , KITCHIN N , et al . Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents [J ] . The New England Journal of Medicine , 2021 , 385 ( 3 ): 239 - 250 .

POLACK F P , THOMAS S J , KITCHIN N , et al . Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine [J ] . The New England Journal of Medicine , 2020 , 383 ( 27 ): 2603 - 2615 .

WANG Q , IKETANI S , LI Z T , et al . Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants [J ] . Cell , 2023 , 186 ( 2 ): 279 - 286.e8 .

ZHANG N N , LI X F , DENG Y Q , et al . A thermostable mRNA vaccine against COVID-19 [J ] . Cell , 2020 , 182 ( 5 ): 1271 - 1283.e16 .

CHEN G L , LI X F , DAI X H , et al . Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial [J ] . The Lancet Microbe , 2022 , 3 ( 3 ): e193 - e202 .

LUM F M , TORRES-RUESTA A , TAY M Z , et al . Monkeypox: disease epidemiology, host immunity and clinical interventions [J ] . Nature Reviews Immunology , 2022 , 22 ( 10 ): 597 - 613 .

EBIoMEDICINE . Monkeypox virus outbreak: can evolution guide us to new treatments or vaccines? [J ] . EBioMedicine , 2022 , 82 : 104221 .

WHO . Multi-country monkeypox outbreak in non-endemic countries [EB/OL ] . ( 2022-05-21 )[ 2023-10-01 ] . https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385 https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385 .

ZUMLA A , VALDOLEIROS S R , HAIDER N , et al . Monkeypox outbreaks outside endemic regions: scientific and social priorities [J ] . The Lancet Infectious Diseases , 2022 , 22 ( 7 ): 929 - 931 .

DUQUE M P , RIBEIRO S , MARTINS J V , et al . Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022 [J ] . Eurosurveillance , 2022 , 27 ( 22 ): 2200424 .

VIVANCOS R , ANDERSON C , BLOMQUIST P , et al . Community transmission of monkeypox in the United Kingdom, April to May 2022 [J ] . Eurosurveillance , 2022 , 27 ( 22 ): 2200422 .

WHO . 2022 - 23 Mpox (Monkeypox) outbreak:global trends [EB/OL ] . [ 2024-01-26 ] . https://worldhealthorg.shinyapps.io/mpx_global/ https://worldhealthorg.shinyapps.io/mpx_global/ .

TARÍN-VICENTE E J , ALEMANY A , AGUD-DIOS M , et al . Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study [J ] . The Lancet , 2022 , 400 ( 10353 ): 661 - 669 .

PAULI G , BLÜMEL J , BURGER R , et al . Orthopox viruses: infections in humans [J ] . Transfusion Medicine and Hemotherapy , 2010 , 37 ( 6 ): 351 - 364 .

ROBERTS K L , SMITH G L . Vaccinia virus morphogenesis and dissemination [J ] . Trends in Microbiology , 2008 , 16 ( 10 ): 472 - 479 .

HOOPER J W , CUSTER D M , THOMPSON E . Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman Primates [J ] . Virology , 2003 , 306 ( 1 ): 181 - 195 .

MUCKER E M , GOLDEN J W , HAMMERBECK C D , et al . A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge [J ] . Journal of Virology , 2022 , 96 ( 3 ): e0150421 .

HOOPER J W , GOLDEN J W , FERRO A M , et al . Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge [J ] . Vaccine , 2007 , 25 ( 10 ): 1814 - 1823 .

HIRAO L A , DRAGHIA-AKLI R , PRIGGE J T , et al . Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge [J ] . The Journal of Infectious Diseases , 2011 , 203 ( 1 ): 95 - 102 .

SAKHATSKYY P , WANG S X , CHOU T H W , et al . Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen [J ] . Virology , 2006 , 355 ( 2 ): 164 - 174 .

FDA . FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox [EB/OL ] . ( 2019-09-24 )[ 2023-10-01 ] . https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox .

FDA . Key facts about vaccines to prevent monkeypox disease [EB/OL ] . ( 2022-08-18 )[ 2023-10-01 ] . https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-monkeypox-disease https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-monkeypox-disease .

ZAECK L M , LAMERS M M , VERSTREPEN B E , et al . Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals [J ] . Nature Medicine , 2023 , 29 ( 1 ): 270 - 278 .

FREYN A W , ATYEO C , EARL P , et al . A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge [EB/OL ] . bioRxiv ( 2022-12-19 )[ 2023-10-01 ] . https://www.biorxiv.org/content/10.1101/2022.12.17.520886v1 https://www.biorxiv.org/content/10.1101/2022.12.17.520886v1 .

FANG Z H , MONTEIRO V S , RENAUER P A , et al . Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens [J ] . Cell Research , 2023 , 33 ( 5 ): 407 - 410 .

HOU F J , ZHANG Y T , LIU X H , et al . mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge [J ] . Nature Communications , 2023 , 14 ( 1 ): 5925 .

ZHANG R R , WANG Z J , ZHU Y L , et al . Rational development of multicomponent mRNA vaccine candidates against mpox [J ] . Emerging Microbes & Infections , 2023 , 12 ( 1 ): 2192815 .

SANG Y , ZHANG Z , LIU F , et al . Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus [J ] . Signal Transduction and Targeted Therapy , 2023 , 8 ( 1 ): 172 .

ZENG J W , LI Y , JIANG L R , et al . Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge [J ] . Emerging Microbes & Infections , 2023 , 12 ( 1 ): 2204151 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Applications of the recombinant human collagen type Ⅲ-based trimerization motif in the design of vaccines to fight against SARS-CoV-2 and influenza virus

Artificial synthesis and applications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicons

Related Author

LIU Zezhong

ZHOU Jie

ZHU Yun

LU Lu

JIANG Shibo

LIU Zezhong

ZHOU Jie

LU Lu

Related Institution

School of Basic Medical Sciences， Fudan University

Department of Pharmacology， School of Pharmacy， Fudan University

Institute of Biophysics， Chinese Academy of Sciences

Key Laboratory of Medical Molecular Virology （MOE/NHC/CAMS）， School of Basic Medical Sciences， Fudan University

Bioinformatics Center of Academy of Military Medical Sciences

⁰